Beacon Medicare Limited has announced the launching of Nilonix in capsule form under the generic of Nilotinib for the treatment of people, who diagnosed with Philadelphia chromosome positive CML and limatinib resistant Ph+ CML, effectively.
The medicine will be available in two strengthens –150mg and 200mg –capsule and the both packets will contain 120 capsules for only export purpose.
“We believe that the launching of the Nilonix capsule in global arena will enlarge the range of our products and boost image of our company,” a top brass of the company expressed the optimism after launching the product .
Wishing a very successful launching of the Nilonix 150mg and 200mg capsules, the authority said apart from reputation, the volume of sales of the company will also increase in the global market.
Visit Website: www.nilonix.com